ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel


Published on

Presisdent Marc Hedrick presents as part of the Cardiac Cell Therapy at the 1st Annual Regen Med Investor Day

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel

  1. 1. 1st Annual Regen Med Investor DayClinical Outlooks in Cardiovascular Disease Marc Hedrick, MD Cytori Therapeutics (NASDAQ:CYTX) President April 17, 2013
  2. 2. Safe Harbor StatementThis presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. Allstatements, other than statements of historical fact, that address activities, events or developments that weintend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.Such statements are based upon certain assumptions and assessments made by our management in light oftheir experience and their perception of historical trends, current conditions, expected future developmentsand other factors they believe to be appropriate.The forward-looking statements included in this presentation involve known and unknown risks that relate toCytori’s future events or future financial performance and the actual results could differ materially from thosediscussed in this presentation. Risks and uncertainties that may cause Cytoris actual results to differmaterially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’sForm 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. Wewould advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filedwith the United States Securities and Exchange Commission for a more detailed description of these risks.The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptionsonly as of the date of this presentation and Cytori undertakes no duty or obligation to update or revisepublicly any forward-looking statements contained in this presentation as a result of new information, futureevents or changes in Cytori’s expectations.
  3. 3. Cytori Cell Therapy: Unique AttributesProprietary formulation of ADRCs•Autologous•Mixed cell population•Various mechanisms•Patented process•Virtually ‘off the shelf’
  4. 4. Cytori Cell Therapy: Heterogeneity Vascular Mechanisms of Action Smooth Tissue Muscle Cells Macrophages 9% 23% • Paracrine (local GFEndothelial delivery) Cells 7% • Differentiation • Inflammatory modulation • Angiogenesis • Wound healing White Blood CD34+/ Cells CD31- Stem Cells 2% 22% 37%
  5. 5. Cytori Cell Therapy: Cardiovascular Trials EU Pilot US Pilot Pivotal Complete In Progress Acute MI APOLLO ADVANCE N = 14, Europe N = 216, Europe Complete In Progress Preliminary ChronicMyocardial ATHENA II PRECISE ATHENA Ischemia N=TBD, N = 27, Europe N = 45, USA InternationalSummary from European Pilot Trials• AMI- safe and trend toward reduction in infarct size, favorable remodeling• HF & CMI- safe & statistically significant stabilization in Max VO2
  6. 6. Cytori Cell Therapy: EconomicsProcedures / Est. Consumable Est. Consumable Est. Revenue Year ASP Gross Profit 100,000 $10,000 $1 Billion $800 + Million System: • Low six figure ASP (current generation) • Next-generation system COGS~ $10,000, flexible model Per-procedure consumable: • $8,000-$12,000 for vascular indications • >80% GM